<DOC>
	<DOCNO>NCT01337375</DOCNO>
	<brief_summary>In randomize , cross-over , open label study correlation Pegasys ( peginterferon alfa-2a ) pharmacokinetics intravenous ( iv ) subcutaneous ( sc ) administration viral load viral kinetics investigate patient chronic hepatitis C genotype 1 non-responders previous standard combination therapy pegylated interferon ribavirin . Patients randomize receive either weekly twice weekly Pegasys iv sc 2 week , cross mode administration washout period 6 week .</brief_summary>
	<brief_title>A Study Pharmacokinetics And Pharmacodynamics Intravenously Administered Pegasys ( Peginterferon Alfa-2a ) Patients With Chronic Hepatitis C And Previous Non-Response Pegylated Interferon And Ribavirin Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult caucasian patient , 18 70 year age Hepatitis C , genotype 1 Nonresponder previous antiHCV therapy peginterferon alfa ribavirin Compensated liver disease ( ChildPugh class A ) &gt; /= 24 month baseline Positive antiHCV &gt; 6 month , detectable serum HCVRNA Treatmentna√Øve responder previous therapy HCV infection genotype 1 Positive Hepatitis A , Hepatitis B HIV infection screen Chronic Hepatitis HCV origin Decompensated liver disease ( ChildPugh class B C ) Therapy systemic antiviral , antineoplastic immunomodulatory agent 6 month prior study Clinically relevant retina disorder Pregnant lactate woman male partner pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>